SCG Cell Therapy Pte Ltd presented late-breaking data from its first-in-class autologous HBsAg-specific T-Cell receptor-engineered T Cell Therapy – SCG101 – at the International Society for Cell & Gene Therapy conference in Paris, France.
SCG Cell Therapy Pte Ltd presented late-breaking data from its first-in-class autologous HBsAg-specific T-Cell receptor-engineered T Cell Therapy – SCG101 – at the International Society for Cell & Gene Therapy conference in Paris, France.